Edesa Biotech, Inc.

EDSA • Biotechnology

$2.82

▲ +0.04 (+1.44%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL DE MAYOR RIESGOPrecauciónConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Conviene actuar con cautela. Los ratios recientes muestran debilidades que pueden limitar el retorno si los fundamentales no mejoran.

Capitalización

$25.40M

Crecimiento

—

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0Liquidez saludable · 10.67Rentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 16 ago 2026, 12:12 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$2.82

Change1.44%

Shares Out9.01M

Market Cap$25.40M

Enterprise Value$15.07M

52W Range0.72 - 20.32

Beta1.08

P/E-1.80

P/B2.00

P/FCF-2.84

EV/EBITDA-1.05

EV/FCF-1.68

Price$2.82

Change1.44%

Shares Out9.01M

Market Cap$25.40M

Enterprise Value$15.07M

52W Range0.72 - 20.32

Beta1.08

P/E-1.80

P/B2.00

P/FCF-2.84

EV/EBITDA-1.05

EV/FCF-1.68

Earnings Yield-55.52%

FCF Yield-35.24%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq0.00

Current Ratio10.67

Quick Ratio10.67

Volume45.93K

Avg Volume214.97K

EPS Surprise-0.25

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

70/100

Potencial de crecimiento

Ingresos y expansión

50/100

Atractivo del precio

Barata o cara hoy

94/100

Por qué este puntaje▼

Nivel de deuda manejable · 0Liquidez saludable · 10.67Rentabilidad débil

Analyst view

Analyst sentiment and price target

EDSA

Analyst sentiment

Based on 2 analyst votes · 2026-10-21

100/100

Bullish

Hold

Bearish

Resumen de la compañía

IPO: 6/21/2010

Industria: Biotechnology

P/B i: 2.00

Deuda / Patrimonio i: 0.00

Margen operativo: 0.00%

Margen neto: 0.00%

ROE i: -

ROIC: -

Salud financiera

Puntaje14 / 20

Deuda / Patrimonio: 0.00

Ratio corriente: 10.67

Ratio rápido: 10.67

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Nijhawan Pardeep

Transacción: 08/03/2026

COMPRA

Cambio

+5,324

Precio

Not reported

Presentación

08/04/2026

Tipo

COMPRA

Nijhawan Pardeep

Transacción: 07/02/2026

COMPRA

Cambio

+3,378

Precio

Not reported

Presentación

07/02/2026

Tipo

COMPRA

Nijhawan Pardeep

Transacción: 06/16/2026

COMPRA

Cambio

+153,550

Precio

Not reported

Presentación

06/16/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Nijhawan Pardeep	COMPRA	+5,324	Not reported	08/03/2026	08/04/2026
Nijhawan Pardeep	COMPRA	+3,378	Not reported	07/02/2026	07/02/2026
Nijhawan Pardeep	COMPRA	+153,550	Not reported	06/16/2026	06/16/2026
Nijhawan Pardeep	COMPRA	+1,671	Not reported	06/01/2026	06/01/2026
Liu Da David	COMPRA	+19,000	Not reported	05/27/2026	05/29/2026
Nijhawan Pardeep	COMPRA	+96,913	Not reported	05/27/2026	05/29/2026
Olson Charles V	COMPRA	+19,000	Not reported	05/27/2026	05/29/2026
Sistilli Carlo	COMPRA	+19,000	Not reported	05/27/2026	05/29/2026
Brooks Michael J	COMPRA	+64,609	Not reported	05/27/2026	05/29/2026
Weiler Peter J.	COMPRA	+64,609	Not reported	05/27/2026	05/29/2026
Chypyha Joan	COMPRA	+19,000	Not reported	05/27/2026	05/29/2026
MacDonald Sean Arthur	COMPRA	+19,000	Not reported	05/27/2026	05/29/2026
Marshall Patrick	COMPRA	+19,000	Not reported	05/27/2026	05/29/2026
Nijhawan Pardeep	COMPRA	+1,159	Not reported	05/01/2026	05/01/2026
Nijhawan Pardeep	COMPRA	+2,578	Not reported	04/01/2026	04/10/2026
Brooks Michael J	COMPRA	+2,000	$1.57	02/26/2026	03/11/2026
Nijhawan Pardeep	COMPRA	+10,000	$3.90	03/05/2026	03/06/2026
Nijhawan Pardeep	COMPRA	+10,000	$4.26	03/04/2026	03/05/2026
Nijhawan Pardeep	COMPRA	+10,000	$3.63	03/03/2026	03/04/2026
Nijhawan Pardeep	COMPRA	+1,000	$2.28	03/02/2026	03/03/2026

Sobre la compañía

Edesa Biotech, Inc.

Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.

Fuente - Link

Competidores

BRTX COCP DWTX ERNA EVGN IMNN IMRN OSRH SNSE TRAW

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Edesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo Study

TORONTO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for its Phase 2 clinical study of EB06 in vitiligo, enabling Edesa to expand recruitment to the United States. Patient recruitment is underway in Canada and the first U.S. investigational sites are expected to begin enrolling subjects next quarter. Edesa anticipates that topline data will be available fourth quarter 2027.

GlobeNewsWire

Edesa Biotech Announces Pricing of $25.0 Million Public Offering

TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the pricing of an underwritten public offering consisting of (i) 3,870,500 common shares and accompanying common share warrants to purchase an aggregate of 3,870,500 common shares and (ii) in lieu of common shares to investors who so choose, pre-funded warrants to purchase up to 675,000 common shares and accompanying common share warrants to purchase an aggregate of 675,000 common shares, at an exercise price of $0.0001 per pre-funded warrant. Each common share and pre-funded warrant is being sold in combination with an accompanying common share warrant to purchase one common share. The common share warrants will have an exercise price of $7.50 per share, will be immediately exercisable from the date of issuance and will expire on the earlier of (x) the 18-month anniversary of the original issuance date and (y) 30 days following the Company's public announcement of Phase 2 vitiligo topline data for EB06. The combined public offering price of each common share and accompanying common share warrant is $5.50. The combined public offering price of each pre-funded warrant and accompanying common share warrant is $5.4999, which represents the combined public offering price for the common shares and accompanying common share warrants less the $0.0001 per share exercise price for each pre-funded warrant. The gross proceeds are expected to be approximately $25.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, Edesa has granted the underwriters a 30-day option to purchase up to an additional 681,825 common shares and accompanying common share warrants to purchase up to 681,825 common shares at the public offering price, less underwriting discounts and commissions.

GlobeNewsWire

Edesa Biotech Announces Proposed Public Offering

GlobeNewsWire

Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results

TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and nine months ended June 30, 2026 and provided an update on its business.

GlobeNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-14	-0.24	-0.49	-0.25
2026-02-13	-0.28	-0.28	0
2025-12-12	-0.27	-0.32	-0.05
2025-08-08	-0.26	-0.25	0.01
2025-05-14	-0.3	-0.3	0
2025-02-14	-0.31	-0.48	-0.17
2024-12-13	-0.54	-0.29	0.25
2024-08-09	-0.58	-0.52	0.06
2024-05-10	-0.69	-0.58	0.11
2024-02-09	-1.21	-0.54	0.67
2023-12-15	-0.71	-0.6	0.11
2023-08-09	-1.19	-0.7	0.49